Zobrazeno 41 - 50
of 18 481
pro vyhledávání: ''
Autor:
Charles E. Foucar, Rupali Roy Bhave, Darren King, Bernard L. Marini, Dan R. Robinson, Dale L. Bixby, Anthony J. Perissinotti, Lydia L. Benitez, Vincent Ma
Publikováno v:
Cancer Genetics. :57-60
The cornerstone of management in patients with acute promyelocytic leukemia (APL) is early diagnosis and prompt initiation of treatment with an all-trans retinoic acid (ATRA)-based regimen. Identification of the t(15;17)(PML-RARA) chromosomal translo
Autor:
Sabrina A. Hogan, Reinhard Dummer, Alexander M. Menzies, Florentia Dimitriou, Georgina V. Long
Publikováno v:
European Journal of Cancer. 157:214-224
Background Immune checkpoint inhibitors (ICIs) have activity across many tumor types, but activation of the immune system may also lead to significant, often steroid-refractory immune-related adverse events (irAEs). We sought to determine the activit
Autor:
Marie C Semira, Francis Parnis, Angelyn Anton, Peter Gibbs, Arun Azad, Javier Torres, Lavinia Spain, Ashray Gunjur, Andrew Weickhardt, Phillip Parente, Jeffrey C. Goh, Edmond M. Kwan, Shirley Wong, Ben Tran, Carmel Pezaro, J. Shapiro
Publikováno v:
European Journal of Cancer. 157:485-492
INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related events (SREs), including symptomatic skeletal events (SSEs). Bone-modifying agents (BMAs) delay SREs and SSEs. However, the
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Publikováno v:
Future Oncology. 17:4249-4261
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II stud
Publikováno v:
JCO Precision Oncology. :849-853
Publikováno v:
Anticancer Research. 41:5729-5737
Background/aim This study aimed to identify the predictive markers for carboplatin-induced severe thrombocytopenia. Patients and methods We conducted a retrospective cohort analysis of inpatients who received carboplatin and pemetrexed. Results Among
Autor:
Amy S. Ruppert, Larry Beaver, Bonnie K. Harrington, Janek S. Walker, Brandi R. Walker, Katie Williams, James Cronin, Zachary A. Hing, Alexander Pan, Jordan N. Skinner, Jennifer A. Woyach, Nyla A. Heerema, Steven Sher, Amy Lehman, Charles Thomas Gregory, Vincenzo Coppola, Rosa Lapalombella, Krzysztof Mrózek, Max Yano, Pearlly S. Yan, Hatice Gulcin Ozer, James S. Blachly, Jadwiga Labanowska, John C. Byrd, Casey Cempre
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications
Nature Communications
Rare, recurrent balanced translocations occur in a variety of cancers but are often not functionally interrogated. Balanced translocations with the immunoglobulin heavy chain locus (IGH; 14q32) in chronic lymphocytic leukemia (CLL) are infrequent but
Autor:
Jan Borén, Levent M. Akyürek, Per Fogelstrand, Matias Ekstrand, Joakim Karlsson, Max Levin, Malin Levin, Keith E. Mostov, Lars Ny, Martin O. Bergo, Jonas Nilsson, Sara Bjursten, Zhiyuan Zhao, Kristell Le Gal, Andrew J. Ewald, Ankur Pandita
Publikováno v:
The American journal of pathology, vol 191, iss 11
Am J Pathol
Am J Pathol
Angiogenesis supplies oxygen and nutrients to growing tumors. Inhibiting angiogenesis may stop tumor growth, but vascular endothelial growth factor inhibitors have limited effect in most tumors. This limited effect may be explained by an additional,
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
BMC Cancer
BMC Cancer
Background Breast cancer (BC) is one of the major malignancies worldwide. Circular ribonucleic acids (circRNAs) are a class of conserved ribonucleic acid (RNA) molecules that play important roles in various diseases. Recently, circRNAs have been sugg